Get the Stockscreener App
3.08
6.95%
-0.23
Pre-market:
3.23
0.15
+4.87%
Cervomed Inc stock is traded at $3.08, with a volume of 865.46K.
It is down -6.95% in the last 24 hours and up +25.71% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$3.31
Open:
$3.33
24h Volume:
865.46K
Relative Volume:
0.17
Market Cap:
$28.52M
Revenue:
$2.09M
Net Income/Loss:
$-30.04M
P/E Ratio:
-0.9423
EPS:
-3.2685
Net Cash Flow:
$-27.57M
1W Performance:
-9.94%
1M Performance:
+25.71%
6M Performance:
-55.94%
1Y Performance:
-56.68%
1-Day Range:
$3.05
$3.33
1-Week Range:
$3.05
$3.7899
52-Week Range:
$2.13
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.08 | 30.65M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CervoMed Inc. Announces New Clinical Data for Neflamapimod in Dementia with Lewy Bodies at AAIC 2026 - Minichart
CervoMed (NASDAQ: CRVO) highlights DLB trial data and Phase 3 plans - Stock Titan
CervoMed selects 50 mg Phase 3 dose - grafa.com
CervoMed Inc. Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in Treatment of Dementia with Lewy Bodies - marketscreener.com
CervoMed presents dementia drug data at AAIC 2026 conference - Investing.com
CervoMed Reports Stable Right Basal Forebrain Volume Over 48 Weeks - Stock Titan
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment - Investing.com
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment By Investing.com - Investing.com Nigeria
CRVO Reiterates Buy Rating by HC Wainwright -- Price Target Main - GuruFocus
[EFFECT] CervoMed Inc. SEC Filing - Stock Titan
CervoMed (NASDAQ: CRVO) registers 10,081,131 private placement shares for resale - Stock Titan
CervoMed Completes Phase 2 Enrollment of Neflamapimod for Frontotemporal Dementia; Interim Data Accepted at CTAD Conference 9 – Minichart - Minichart
CervoMed completes enrollment in Phase 2a nfvPPA trial; interim biomarker data slated for CTAD - TradingView
CervoMed (NASDAQ: CRVO) finishes Phase 2a nfvPPA enrollment and schedules CTAD data - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
CervoMed finalizes Phase 2a enrollment for nfvPPA frontotemporal dementia - grafa.com
CervoMed (CRVO) Completes Enrollment in Phase 2a Study for nfvPP - GuruFocus
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia - Moomoo
CervoMed completes enrollment in phase 2a nfvPPA trial - Investing.com
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target - Investing.com India
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target By Investing.com - Investing.com Canada
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - The Manila Times
CervoMed completes enrollment in phase 2a nfvPPA trial By Investing.com - Investing.com UK
CervoMed finishes Phase 2 study in rare dementia with no U.S. or EU treatment - Stock Titan
CRVO Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue R&D InvestmentEBITDA Margin Trends - dars.gov.et
Morgan Stanley Ceases >5% Beneficial Ownership in CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed Q1 2026 Earnings: EPS Misses Estimates, Stock Rallies 1.46% Amid Pipeline ProgressEarnings Stability Report - dars.gov.et
Cash flow from operating activities of CervoMed Inc. – DUS:DP8 - TradingView
CervoMed files prospectus for offer and resale of 10.08M shares - scanx.trade
Form S-3 CervoMed Inc For: 6 July By Investing.com - Investing.com Nigeria
CRVO Set to Offer 10.08 Million Shares for Sale - GuruFocus
[S-3] CervoMed Inc. Shelf Registration Statement - Stock Titan
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 - The Manila Times
CervoMed puts neflamapimod data on DLB in five AAIC talks - Stock Titan
Enterprise value to revenue forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Price to earnings forward of CervoMed Inc. – FWB:DP8 - TradingView
$CervoMed (CRVO.US)$ - Moomoo
Price to book forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Price to book forward of CervoMed Inc. – DUS:DP8 - TradingView
Price to sales forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Enterprise value to EBITDA forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
Enterprise value to EBIT forward of CervoMed Inc. – DUS:DP8 - TradingView
Enterprise value to EBITDA forward of CervoMed Inc. – DUS:DP8 - TradingView
Enterprise value to revenue forward of CervoMed Inc. – DUS:DP8 - TradingView
CRVO Q1 2026 Earnings: EPS Misses Estimates Amid R&D Spending; Stock Rises 4.18%Guidance Upgrade Report - DonanımHaber
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed (CRVO) Schedule 13G: Manager-linked 750,000-share holding - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on CervoMed (CRVO) - The Globe and Mail
CRVO stock rockets nearly 100% on patent win before offering news cools rally - MSN
CervoMed Inc. Actuals & Estimates (NASDAQ:CRVO) - TradingView
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):